Cefotaxime diffusion into cerebrospinal fluid of children with meningitis

Cefotaxime diffused consistently and in therapeutic levels into the cerebrospinal fluid (CSF) of 13 children successfully treated for bacterial meningitis. CSF cefotaxime levels early (6.0 micrograms/ml) and late (1.2 micrograms/ml) in treatment were severalfold the MBCs for the infecting organisms. After a single 40-mg/kg dose to each of five infants with ventriculostomies, mean CSF levels of cefotaxime were 6.4, 5.7, and 4.5 micrograms/ml at 2, 4, and 6 h, respectively.

[1]  H. Neu.  The pharmacokinetics of new cephalosporins: significance in clinical practice. , 1984, Bulletin of the New York Academy of Medicine.

[2]  C. Cherubin,et al.  Concentrations of cefotaxime and the desacetyl metabolite in serum and CSF of patients with meningitis. , 1984, The Journal of antimicrobial chemotherapy.

[3]  J. Ernst,et al.  Correlation of in vitro time-kill curves and kinetics of bacterial killing in cerebrospinal fluid during ceftriaxone therapy of experimental Escherichia coli meningitis , 1983, Antimicrobial Agents and Chemotherapy.

[4]  J. Doluisio.  Clinical pharmacokinetics of cefotaxime in patients with normal and reduced renal function. , 1982, Reviews of infectious diseases.

[5]  R. Ings,et al.  The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. , 1982, Reviews of infectious diseases.

[6]  M. Rouan,et al.  Determination of cefsulodin, cefotiam, cephalexin, cefotaxime, desacetyl-cefotaxime, cefuroxime and cefroxadin in plasma and urine by high-performance liquid chromatography. , 1982, Journal of chromatography.

[7]  C. Papadatos,et al.  Treatment of severe neonatal infections with cefotaxime. Efficacy and pharmacokinetics. , 1982, The Journal of pediatrics.

[8]  G. Mccracken,et al.  Relation of concentrations of Haemophilus influenzae type b in cerebrospinal fluid to late sequelae of patients with meningitis. , 1982, The Journal of pediatrics.

[9]  R. Kauffman,et al.  Relative bioavailability of intravenouschloramphenicol succinate and oral chloramphenicol palmitate in infants and children , 1981 .

[10]  C. J. Baker,et al.  Antagonism of ampicillin and chloramphenicol for meningeal isolates of group B streptococci , 1981, Antimicrobial Agents and Chemotherapy.

[11]  R. Kauffman,et al.  Pharmacokinetics of chloramphenicol and chloramphenicol succinate in infants and children. , 1981, The Journal of pediatrics.

[12]  H. Neu,et al.  Cefotaxime kinetics after intravenous and intramuscular injection of single and multiple doses , 1980, Clinical pharmacology and therapeutics.

[13]  B. Belohradsky,et al.  INTRAVENOUS CEFOTAXIME IN CHILDREN WITH BACTERIAL MENINGITIS , 1980, The Lancet.

[14]  R. Wise,et al.  HR 756, a Highly Active Cephalosporin: Comparison with Cefazolin and Carbenicillin , 1978, Antimicrobial Agents and Chemotherapy.

[15]  J. Hamilton-miller,et al.  Cefotoxime (HR 756) a new cephalosporin with exceptional broad-spectrum activity in vitro. , 1978, The Journal of antimicrobial chemotherapy.

[16]  A. Dajani,et al.  Ampicillin-chloramphenicol interaction against enteric Gram-negative organisms. , 1983, Pediatric infectious disease.

[17]  R. Kauffman,et al.  Relative bioavailability of intravenous chloramphenicol succinate and oral chloramphenicol palmitate in infants and children. , 1981, The Journal of pediatrics.

[18]  J. Mcewen,et al.  Metabolism of cefotaxime in animals and man. , 1980, The Journal of antimicrobial chemotherapy.